MLTX
MoonLake Immunotherapeutics
$17.06
-0.81%
2026-05-08
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
Key Fundamentals
Forward P/E
-4.72
EPS (TTM)
$-3.53
ROE
-60.8%
Profit Margin
0.0%
Debt/Equity
24.86
Price/Book
4.01
Beta
1.01
Market Cap
$1.25B
Avg Volume (10D)
658K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$19.73
60D Low
$15.27
Avg Volume
1.1M
Latest Close
$17.06
Get breakout alerts for MLTX
Sign up for Breakout Scanner to receive daily notifications when MLTX triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
MoonLake Immunotherapeutics (MLTX) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors MLTX daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. MLTX operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.